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Abstract
Background: Airway wall remodelling is a key pathology of asthma. It includes thickening of the airway wall,
hypertrophy and hyperplasia of bronchial smooth muscle cells (BSMC), as well as an increased vascularity of the
sub-epithelial cell layer. BSMC are known to be the effector cells of bronchoconstriction, but they are increasingly
recognized as an important source of inflammatory mediators and angiogenic factors.
Objective: To compare the angiogenic potential of BSMC of asthmatic and non-asthmatic patients and to identify
asthma-specific angiogenic factors.
Methods: Primary BSMC were isolated from human airway tissue of asthmatic and non-asthmatic patients.
Conditioned medium (CM) collected from BSMC isolates was tested for angiogenic capacity using the endothelial cell
(EC)-spheroid in vitro angiogenesis assay. Angiogenic factors in CM were quantified using a human angiogenesis
antibody array and enzyme linked immunosorbent assay.
Results: Induction of sprout outgrowth from EC-spheroids by CM of BSMC obtained from asthma patients was
increased compared with CM of control BSMC (twofold, p < 0.001). Levels of ENA-78, GRO-α and IL-8 were
significantly elevated in CM of BSMC from asthma patients (p < 0.05 vs. non-asthmatic patients). SB 265610, a
competitive antagonist of chemokine (CXC-motif) receptor 2 (CXCR2), attenuated the increased sprout outgrowth
induced by CM of asthma patient-derived BSMC.
Conclusions: BSMC isolated from asthma patients exhibit increased angiogenic potential. This effect is mediated
through the CXCR2 ligands (ENA78, GRO-α and IL-8) produced by BSMC.
Implications: CXCR2 ligands may play a decisive role in directing the neovascularization in the sub-epithelial cell
layers of the lungs of asthma patients. Counteracting the CXCR2-mediated neovascularization by pharmaceutical
compounds may represent a novel strategy to reduce airway remodelling in asthma.
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Introduction
Asthma is a chronic inflammatory airway disease affecting
over 300 million people worldwide with an expected increase of
a further 100 million by 2025 [1,2]. Although airway
inflammation in asthma can be controlled, there is currently no
cure for the disease and airway wall remodelling is unaffected
by any asthma therapy. The etiology of asthma remains
obscure and the pathology of asthma involves genetic
predisposition and environmental factors. Increasing evidence
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suggests that inflammation is not the only cause of asthma and
airway remodelling may be equally important [3]. Airway wall
remodelling refers to persistent cellular and structural changes
in the airway wall. In progressive disease, airway remodelling
includes epithelial goblet cell hypertrophy, enhanced collagen
deposition and airway wall hyperplasia [4-6].
It has been shown that bronchial smooth muscle cells
(BSMC) isolated from asthma patients release more pro-
inflammatory mediators than BSMC from control subjects [7-9].
These findings suggest that BSMC of asthma patients exhibit a
hyper-reactive “primed” phenotype, which may be explained, at
least in part, by an aberrant expression of the transcription
regulator CCAAT/enhancer binding protein α (C/EBPα)
[7,10-12].
Histological studies of airways in adults and children with
asthma have variously provided evidence for increased
microvessel density/vascularity and increased numbers of
BSMC [13-17]. Increased airway vascularity has also been
demonstrated in vivo in asthmatic patients by
bronchovideoscopy [18]. Vascular endothelial growth factor
(VEGF), a mediator of microvascular leakage, EC proliferation
and vascular remodelling, was found to be expressed in the
airways of asthma patients [19,20]. Furthermore, increased
levels of angiogenin and monocyte chemotactic protein-1
(MCP-1) were also found in the airways and airway lining fluids
(broncho alveolar lavage fluid, sputum) of asthma patients [21].
More recently it was reported that BSMC were a source of
angiogenic factors [22-24] and that BSMC derived from asthma
patients could initiate and sustain angiogenesis in vitro through
release of VEGF [24]. These data suggest that BSMC may
direct neovascularization in sub-epithelial cell layers in the
airways of asthma patients. In addition, CXCR2 ligands have
been implicated in angiogenesis but mainly in the context of
tumor neovascularization [25]. Here we hypothesize that
CXCR2 ligands may also be involved in asthma associated
airway wall angiogenesis. Better knowledge of the spectrum of
potential angiogenic factors expressed by BSMC is crucial to
therapy of angiogenesis-driven airway remodelling in asthma.
Using in vitro angiogenesis assay, angiogenesis antibody
array, enzyme linked immunosorbent assay (ELISA) and a
competitive CXCR2-selective antagonist, this study
demonstrates that BSMC derived from asthma patients exhibit




Human airway tissue was obtained from explanted and
resected lungs and post mortem organ donors with ethical
approval from The University of Sydney and participating
hospitals (Concord Repatriation General Hospital, Sydney
South West Area Health Service and Royal Price Alfred
Hospital) for sample collection. All volunteer, or their next of
kin, provided written informed consent. The use of human
primary BSMC was approved by local ethical committees
(University Hospital, Basel, Switzerland, and University
Hospital, Groningen, The Netherlands). Written consent was
provided by each patient.
Histochemistry of human airway tissue
Human airway tissue was obtained from asthmatic patients
and from healthy organ donors whose lungs were deemed unfit
for use in a transplant procedure (for the samples used as non-
diseased controls). Airway tissues were fixed in 4% phosphate-
buffered formalin (pH 7.2) and embedded in paraffin. Sections
of 3 µm thickness were stained with Milligan’s trichrome and
imaged using an Olympus BX60 microscope (Olympus,
Hamburg, Germany) equipped with a DP71 camera (Olympus).
Isolation of primary BSMC from human airway tissue
and preparation of conditioned medium
Human airway tissues from 8 non-asthmatic (NA) and 9
asthmatic (A) patients were obtained either by endobronchial
biopsy or therapeutic lung resection. BSMC were isolated from
each individual tissue as described before [26,27]. BSMC
isolates were normally grown in BSMC growth medium (RPMI
1640 supplemented with 5% fetal calf serum (FCS), 1x
antibiotics-antimycotics and 1x modified Eagle`s medium
vitamin mix (Invitrogen, Lubio, Luzern, Switzerland)) under
normoxic conditions (20% O2, 5% CO2, 37 °C). BSMC were
used at passages 3-10.
For the preparation of conditioned medium (CM), BSMC
were seeded at 105 cells/well in 6-well plates and grown in
normal growth medium for 24 h. Cells were subjected to a 24 h
period of serum-deprivation and then further cultured for 24 h
and 72 h under resting (serum-deprived) or normal growth (5%
FCS-containing) conditions. Proliferation experiments showed
that cell numbers between asthmatics and non-asthmatics did
not significantly differ in our experimental setting (fold increase
in cell number after 72 h: asthmatics: 2.05 ± 0.15, non-
asthmatics: 1.98 ± 0.21; p = 0.78). Culture supernatants/CM
were harvested, centrifuged to remove cells and stored at -80
°C until use. Every BSMC isolate was used for preparation of
CM. Due to the limited expansion and passaging of primary
BSMC, the CM of different cell isolates could be used in either
the ELISA or the endothelial tube-formation assay with a partial
overlap. All experiments (except endothelial cell tube formation
assay) were performed with cell culture supernatant (24 h and
72 h, serum-deprived) and CM (24 h and 72 h, 5% FCS). For
any given BSMC isolate the experimental protocols for
preparation of CM were performed on at least two independent
occasions and in duplicate for each condition.
Endothelial tube-formation assay
Human microvascular endothelial cell (EC) line HMEC-1 [28]
was normally maintained in EC growth medium (ECGM,
Provitro, Bioconcept, Allschwil, Switzerland) supplemented with
10% FCS under normoxic conditions. Spheroids composed of
500 HMEC-1 cells were prepared using the hanging drop
method [29]. The tube-forming (sprout outgrowth) assay was
performed as previously described [30]. At least 10 spheroids
per gel were embedded within fibrin gels in 48-well plates. Gels
were overlaid with a 1:1 mixture of ECGM supplemented with
2% FCS and either normal BSMC growth medium (to
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determine spontaneous sprout outgrowth) or CM obtained from
FCS-stimulated BSMC (to measure BSMC-dependent sprout
outgrowth). CM (t = 72 h) of BSMC isolates from 3 different
asthmatic patients and 3 different controls were tested. To
block the chemokine (CXC-motif) receptor 2 (CXCR2) the
competitive antagonist SB 265610 [31,32] was included within
the fibrin gel and medium overlay. After incubation for 24 h,
spheroids were fixed in-gel, stained with TRITC-conjugated
phalloidin and sprout outgrowth from each spheroid was
quantitated by morphometric analysis of the length of
outgrowing tubules [30]. For each well the mean of the 10
longest tubules per spheroid was quantitated by morphometric
analysis of the length of outgrowing tubules using AnalySIS
software (Soft Imaging System GmbH, Munich, Germany). This
value was used to calculate the mean ± SEM (n is provided in
the corresponding figure legends)
Viability and proliferation assays
HMEC-1 were seeded at 7.5x104 cells/well in 48-well plates,
grown for 24 h, serum-deprived for 24 h and then further
cultured in ECGM/10% FCS without or with inclusion of SB
265610. Viability was examined after 24 h by Trypan blue
staining and manual cell counting using a Neubauer chamber.
Proliferation was measured after 48 h by enzymatic
disaggregation and cell enumeration using a Beckman Coulter
particle counter Z1 (Nyon, Switzerland).
Immunocytochemistry
HMEC-1 were grown in 48-well-plates to 70% confluency
and fixed in 4% PFA (20 min). Cells were permeabilized by
incubation (5 min) in PBS containing 0.5% Triton X-100 and
1% bovine serum albumin (BSA) and unspecific binding was
blocked by incubation (1 h) in PBS containing 5% BSA. Cells
were incubated for 2 h with either mouse anti-CXCR2 IgG
(Abcam, Lucerna-Chem, Luzern, Switzerland) or non-immune
mouse IgG (DAKO, Baar, Switzerland), washed (PBS
containing 0.05% Triton X-100) and then incubated with FITC-
conjugated secondary anti-mouse IgG (Southern Biotech,
Bioconcept, Allschwil, Switzerland). Nuclei were counterstained
using Hoechst 33342 (200 ng/ml in PBS, 5 min). Images were
taken with an Olympus IX50 inverted microscope equipped
with a Color View II camera; exposure time was constant for
both conditions.
Immunoblotting
Cellular proteins in whole cell lysates were resolved by
electrophoresis and transferred to a nitrocellulose-membrane
as described [11]. Membranes were incubated (2 h, room
temperature) with mouse anti-CXCR2 IgG, washed (3× 10 min)
with Tris-buffered saline containing 0.1% Tween 20 (TBST)
and incubated (1 h, room temperature) with horseradish
peroxidase-conjugated anti-mouse IgG (Santa Cruz Biotech,
Santa Cruz, USA). Membranes were washed (3× 10 min,
TBST) and incubated (5 min) with ECL-substrate (Pierce,
Thermo Fisher Scientific, Lausanne, Switzerland).
Immunoreactive bands were visualized on X-ray films (Fuji
Film, Luzern, Switzerland) developed in a Curix60 film-
processor (Agfa, Dübendorf, Switzerland).
Angiogenesis Antibody Array
To identify angiogenic factors in the CM of FCS-stimulated
BSMC the Human Angiogenesis Antibody Array G Series 1
(RayBiotech Lucerna-Chem, Luzern, Switzerland) specific for
20 angiogenesis-relevant proteins (antibody array map
provided with Figure) was used. The array test was performed
on four separate occasions; on any given occasion CM and cell
culture supernatant of BSMC-derived from asthmatic and non-
asthmatic patients were tested in parallel. BSMC isolates from
4 different asthmatic and 4 different non-asthmatic patients
were used. 100 µl aliquots of undiluted CM/cell culture
supernatant were applied to each sub-array and the expression
levels of angiogenesis-relevant factors were determined
according to the manufacturer’s instructions. Cy3-fluoresence
was measured using a NimbleGen MS 200 microarray Scanner
(Roche, Basel, Switzerland) and signal intensities were
analyzed with AIDA software (Raytest, Straubenhardt,
Germany). Control experiments with BSMC growth or starving
medium respectively were performed and revealed no
unspecific signals due to the culture medium (no FCS or 5%
FCS). Intensity ratios between asthmatic and control samples
were calculated (normalized to the internal reference positive
control); a ratio of ≥ 1.3 was considered significantly different
as indicated by the manufacturer.
Cytokine-ELISA
ELISA kits for epithelial neutrophil-activating protein 78
(ENA-78)/CXCL5, growth regulated oncogene α (GRO-α)/
CXCL1, and VEGF-A were from R&D (Abingdon. UK). ELISA
kit for IL-8/CXCL8 was from Orgenium (Anibiotech, Vantaa,
Finland). ELISAs were performed according to the respective
manufacturer´s instructions. For these experiments, we used
CM of BSMC isolates from 6 different asthmatic patients and 6
different controls.
RT PCR
HMEC-1 cells were plated in a 25 cm2 cell culture flask and
grown to confluency. Cells were washed 2x with DPBS and
total RNA was isolatd using RNeasy Mini kit (Qiagen,
Hombrechtikon, Switzerland) according to the manufacturer`s
instructions. RNA concentration was determined by
spectroscopy (NanoDrop, Witec, Luzern, Switzerland). First
strand DNA was synthesized with m-MLV Reverse
Transcriptase (Promega, ABC, DEF) from 2.5 µg of total RNA.
The obtained cDNA was subjected to amplification with
HotStarTaq Plus DNA polymerase (Qiagen, Hombrechtikon,
Switzerland) using the following primers: forward 5`-
CAGTTACAGCTCTACCCTGCC-3, reverse 5`-
CCAGGAGCAAGGACAGACCCC-3 generating a 451 bp
spanning fragment. PCR conditions were: 5 min 95°C; 32x: 30
sec 98°C, 30 sec 58°C, 1 min 72°C; 10 min 71°C. PCR
products were size-fractioned on a 1% agarose gel, stained
with ethidium bromide and visualized under UV light.
Statistics
Data was analyzed using Microsoft Excel and Graph Pad
Prism software. Assuming normal distribution of the data points
In Asthma CXCR2 Ligands Promote Angiogenesis
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in the spheroid assay [24,33-35], we performed Student`s t-
test. Mann-Whitney test has been performed analyzing the
ELISA data. A p value of < 0.05 was considered significant.
Results
Increased vascularization in human tissue sections
from the lung of asthma patients
Patients with mild to moderate asthma (n = 9, 4 females/5
males, age 23-60 years) had reversible airway obstruction
documented in the past, with median FEV1 of 84.6% of the
predicted value (ranging from 68.5% to 124.9%). Milligan’s
trichrome staining of human airway tissue cross-sections
demonstrated marked differences between non-asthmatic
(Figure 1A) and asthmatic (Figure 1B) patients; the airway
walls of asthmatic patients exhibited hyperplastic epithelium,
increased thickness of the basement membrane, increased
bulk of smooth muscle bundles, as well as increased micro-
vessel density within sub-epithelial cell layers.
Increased angiogenic potential of BSMC obtained from
asthmatics
Angiogenic potential of culture supernatants (CM) collected
from normally growing BSMC of asthmatics and non-
asthmatics was examined using the EC-spheroid in vitro
angiogenesis assay. Spheroids were also cultured in
unconditioned medium (i.e. with medium that had not been
included with BSMC) to control for “spontaneous” sprout
outgrowth. Figure 2 presents representative images of
spheroids (Figure 2A) and the quantitation of sprout outgrowth
into the 3D fibrin-gel matrix as mean tubule length/spheroid
(Figure 2B) after a 24 h culture period. Incubation of EC-
spheroids with CM of BSMC from asthmatic patients resulted in
a twofold increase in sprout outgrowth as compared with CM of
BSMC from non-asthmatic patients (p < 0.001). In the latter,
sprout outgrowth was not significantly different from
“spontaneous” outgrowth (p = 0.43). Thus the angiogenic
potential of BSMC isolates derived from asthmatic patients is
likely due to their secretion of pro-angiogenic factors into
culture supernatants.
Figure 1.  Milligan’s trichrome stained sections of airway tissue from non-asthmatic (A) and asthmatic (B) patients.  Images
are representative of tissues obtained from 3 non-asthmatic and 3 asthmatic patients. Nuclei and muscle: magenta, collagen: green,
RBC: orange. Note epithelial hyperplasia, thickening of muscle bundles and basement membrane, and increased micro-vessel
density in asthmatic airways. E = epithelium, MB = muscle bundles, BM = basement membrane, MV = micro-vessels.
doi: 10.1371/journal.pone.0081494.g001
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Identification of differentially expressed angiogenic
factors in BMSC of asthmatics vs. non-asthmatics
We used a RayBio angiogenesis antibody array to identify
and compare expression levels of soluble BSMC-derived
angiogenic and angiostatic factors in the CM of normally
growing BSMC derived from non-asthmatic and asthmatic
patients (Figure 3A-3D and S1) in a qualitative way. The array
identified six factors that were present at higher levels in the
CM of BSMC obtained from asthmatics patients, namely
angiogenin, ENA-78/CXCL5, GRO-α/CXCL1, IL-6, IL-8/CXCL8
and MCP-1/CCL2 (Figure 3D). ENA-78/CXCL5, GRO-α/CXCL1
and IL-8/CXCL8 share the same receptor (CXCR2), and have
therefore been the focus of all further studies.
Increased CXCR2-ligands secretion by BSMC of
asthmatics
To validate the array findings quantitatively we elected to
measure levels of GRO-α , ENA-78 and IL-8 in CM by ELISA;
these all belong to the family of CXC-chemokines and signal
via the shared receptor CXCR2 [36]. After 24 h resting culture
conditions (without FCS) BSMC from asthma patients and
control subjects secreted comparable amounts of GRO-α and
ENA-78 and IL-8 (Table 1). After 72 h resting conditions levels
of GRO-α, IL-8, and ENA-78 were significantly greater in CM of
BSMC from asthmatic patients than from non-asthmatic
patients (p < 0.05) (Table 1). Figure 4 shows levels of the
measured secreted chemokines in CM from each of the tested
BSMC after 24 h or 72 h periods of culture under normal
growth conditions (presence of 5% FCS). Levels of GRO-α
(Figure 4A), IL-8 (Figure 4B) and ENA-78 (Figure 4C) were
significantly greater in CM of BSMC from asthmatic patients
than from non-asthmatic patients (p < 0.05; all values
summarized in Table 1). Figure S2 illustrates the high variance
between cell isolates of different patients with respect to the
concentrations and predominance of specific CXCR2
angiogenic factors.
Figure 2.  Angiogenesis assay in vitro.  A, Images illustrating sprout outgrowth from EC-spheroids incubated with unconditioned
control medium or CM from BSMC. B, Lengths of sprouts outgrowing from every spheroid were measured and the mean of the
longest 10 sprouts was calculated. Experiments were performed on 3 separate occasions using control medium and CM derived
from 3 different non-asthmatic (NA) and asthmatic (A) patients. Values are given as mean ± SD. *** p < 0.001.
doi: 10.1371/journal.pone.0081494.g002
In Asthma CXCR2 Ligands Promote Angiogenesis
PLOS ONE | www.plosone.org 5 December 2013 | Volume 8 | Issue 12 | e81494
Figure 3.  Human angiogenesis antibody array.  Examples of the angiogenesis antibody array (exp. 3) comparing CM from
BSMC of non-asthmatic (A) and asthmatic (B) patients. C, Antibody array map. Standard abbreviations for the detected proteins are
used, Pos: positive control, Neg: negative control, IC1-IC3: internal controls 1-3. D, Quantitative analysis from each of the 4
independent experiments performed. Intensity ratios (A:NA) in a paired analysis are shown. Upregulation in any single experiment is
indicated by a cross. nq = not quantifiable (out of range).
doi: 10.1371/journal.pone.0081494.g003
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Previously, Simcock et al. demonstrated that VEGF was the
predominant factor released by TGF-β1- and/or IL-13-
stimulated BSMC and BSMC of asthma patients increased
endothelial cell tube formation through VEGF [24]. Therefore,
we screened our samples for VEGF protein by ELISA. BSMC
obtained from asthmatics secreted significantly more VEGF
compared to non-asthmatics (301 ± 48 pg/ml versus 179 ± 34
pg/ml, respectively; mean ± SEM; p < 0.05, Figure S3).
Increased angiogenic potential of BSMC obtained from
asthmatics is reversed by blocking CXCR2 with the
competitive agonist SB 265610
Since GRO-α, ENA-78 and IL-8 exert their biological effects
through CXCR2, their proangiogenic actions should be
attenuated by the competitive CXCR2-selective antagonist SB
265610. CXCR2 expression by HMEC-1 cells was
demonstrated by RT PCR analysis of total RNA from HMEC-1
cells (Figure 5A); amplification of cDNA with CXCR2 specific
primer demonstrates CXCR2 expression from HMEC-1 cells.
Immunofluorescence staining protocols confirmed the presence
of CXCR2 on HMEC-1 cells (Figure 5B). SB 265610 did not
affect proliferation (Figure 5C) or viability (Figure 5D) of
HMEC-1 monolayers (in ECGM/10% FCS). Furthermore, SB
265610 added alone did not affect basal sprout outgrowth in
the EC-spheroid assay (data not shown). In contrast sprout
outgrowth induced by CM of BSMC from asthma patients was
markedly attenuated (p < 0.001) by SB 265610, even at the
lowest dose (Figure 5E).
Discussion
This study has demonstrated that BSMC from asthma
patients have an increased angiogenic potential compared to
BSMC from non-asthma control subjects. Angiogenesis
antibody arrays revealed that CM of BSMC from asthma
patients contained significantly higher levels of angiogenin,
ENA-78, GRO-α, IL-6, IL-8 and MCP-1. Increased production
of the CXCR2 ligands ENA-78, GRO-α and IL-8 was confirmed
by ELISA and functionality of CXCR2 ligands in mediating
proangiogenic effects of BSMC from asthma patients was
demonstrated by reduction of EC sprout outgrowth in the
presence of the specific CXCR2 antagonist SB 265610.
Neovascularization is increasingly recognized as an
important feature of airway wall remodelling in asthma and it
has become a topic of major interest. The Milligan’s Trichrome
staining of airway tissue sections presented in this study
demonstrated that neovascularization occurs in close proximity
to BSMC. Therefore, BSMC may play a more important role in
the process of angiogenesis than previously considered.
Several studies have examined mechanisms underlying
angiogenesis in airway wall remodelling, and demonstrated
roles for basic fibroblast growth factor (bFGF), angiogenin,
endostatin and VEGF [20,21,24,37-39]. The study by Simcock
et al. is of particular interest because they also used human
airway smooth muscle cells isolated from non-asthmatic and
asthmatic patients and a similar angiogenesis antibody array to
that used in this study [24]. They found that BSMC from
asthmatic patients produced higher levels of angiogenin,
angiopoietin, VEGF, EGF, IGF-1, IFNγ, TIMP-1 and TIMP-2 in
response to stimulation with either IL-13 or TGF-β [20,24]. We
found that in the presence of 5% FCS human BSMC of asthma
patients released a different complement of angiogenic
regulators including angiogenin, IL-6, MCP-1 and importantly
three CXCR2 ligands, namely ENA-78, GRO-α and IL-8. ELISA
assay revealed that BSMC of asthma patients also released
significantly more VEGF than BSMC of controls. However,
VEGF levels were low compared to other studies (pg/ml range
rather than ng/ml) [20,24] and below concentrations generally
used to induce in vitro angiogenesis [24,30,40]. The very low
concentration of VEGF in CM of FCS-cultured BSMC may
explain why we could not detect VEGF with the antibody array
we used. The discrepancy between the two studies regarding
VEGF expression might be due to the use of different antibody
array techniques (membrane [24] versus glass platform based
array). It is also likely that production of any specific set of
angiogenic regulators by BSMC is context dependent and is
defined by the microenvironmental setting, meaning that
stimulation with IL-13 or TGF-β20 may induce a distinctly
different set of angiogeneic factors relative to . stimulation with
FCS. Additionally, intra-and inter-study variations with respect
to specific composition and quantity of angiogenic factors
produced might also reflect the heterogeneous character of
Table 1. Summary of the levels (ng/ml) of CXCR2 ligands GRO-α, IL-8 and ENA-78 in CM of BSMC from non-asthmatic
(NA) and asthmatic (A) patients (n = 6 per group) after 24 h and 72 h culture under resting (serum-free) and normal growth
(presence of 5% FCS) conditions.
 FCS (5%) 24 hours   72 hours   
  NA A p-value NA A p-value
GRO-α - 0.49 ± 0.30 0.60 ± 0.26 0.370 2.54 ± 1.66 3.50 ± 0.87 0.002
 + 2.24 ± 1.00 5.68 ± 2.00 >0.0001 4.40 ± 2.01 10.10 ± 3.23 0.022
IL-8 - 1.27 ± 0.47 1.69 ± 1.02 0.750 1.51 ± 0.51 5.82 ± 3.53 0.026
 + 3.80 ± 1.22 9.67 ± 2.05 0.002 5.23 ± 1.34 12.42 ± 2.08 0.002
ENA-78 - 0.11 ± 0.04 0.07 ± 0.03 0.625 0.23 ± 0.16 0.32 ± 0.12 0.016
 + 0.42 ± 0.23 0.89 ± 0.33 0.021 1.00 ± 0.60 1.62 ± 0.72 0.023
p-values were calculated using Mann Whitney U test.
doi: 10.1371/journal.pone.0081494.t001
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Figure 4.  Chemokine release from BSMC derived from asthmatics and non-asthmatics.  Concentrations of GRO-α (A), IL-8
(B) and ENA-78 (C) in CM were collected from BSMC of non-asthmatic (NA) and asthmatic (A) patients after 24 h and 72 h were
determined by ELISA.* p < 0.05 (n = 6).
doi: 10.1371/journal.pone.0081494.g004
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Figure 5.  Involvement of CXCR2 in BSMC-induced neovascularization.  A, RT-PCR of CXCR2 in HMEC-1. B,
Immunofluorescence detection of CXCR2 on HMEC-1. C, D, HMEC-1 monolayers under normal EC growth conditions were
cultured without or with SB 265610 for 48h (C) or 24h (D) (mean ± SD, n=3) and evaluated for proliferation (C) and viability (D). E,
Effect of SB 265610 on sprout outgrowth induced by CM of BSMC from asthmatics. Values are mean ± SEM after normalization to
the control condition. *** p < 0.001 (n ≥ 3).
doi: 10.1371/journal.pone.0081494.g005
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asthma [41]. Nonetheless, both studies underscore the
importance of enhanced release of angiogenic factors by
BSMC from asthmatic patients.
CXCR2 ligands are known mediators of angiogenesis mainly
in the context of tumor angiogenesis [25] and in other diseases
like idiopathic pulmonary fibrosis [42,43] where angiogenesis
plays a role. To the best of our knowledge the increased
release of this set of CXCR2 ligands (ENA-78, GRO-α and
IL-8) from BSMC from asthmatic patients stimulated with FCS
has not been reported before; neither has this release been
linked to the induction of angiogenesis in the context of asthma
airway remodelling. ENA-78, GRO-α and IL-8 all mediate their
angiogenic effect through CXCR2, although IL-8 has also been
shown to bind the CXCR1-receptor [44]. Our findings point
toward a previously unrecognized role for CXCR2 and its
ligands in directing EC activation and neovascularization in
asthma specifically, because lower levels (2- to 3-fold) of these
ligands present in CM of non-asthmatic controls did not
significantly induce sprout outgrowth from EC spheroids. This
may indicate that only BSMC obtained from asthmatics
produce sufficient factors to reach the threshold required to
induce of sprouting.
CXCR2 is expressed in several different tissues and cell
types including cells of the immune system, epithelial cells, EC
and cells of the nervous system [45]. Our study showed that
CXCR2 is expressed on HMEC-1 and functionally relevant
since CXCR2 antagonist SB 265610 diminished sprout
outgrowth induced by CM of BSMC from asthmatic patients.
SB 265610 is considered a competitive antagonist and an
allosteric inverse agonist of CXCR2 and has been shown to be
a highly specific inhibitor for this receptor [31]. This observation
may be the first step towards a new specific treatment of
remodelling in the airway wall of asthma patients.
In asthma patients, increased BSMC mass [14,17,27] and
increased number of mitochondria in BSMC [46] have been
observed, which suggests increased energy consumption and
an according prompt for induction of angiogenesis to supply the
cells with nutrition and oxygen. Therefore, reducing
neovascularization in the sub-epithelial cell layers of the airway
wall of asthma patients might help to reduce airway wall
remodelling. Clinical studies have shown that symptoms of
severe asthma could be markedly reduced by the use of
thermoplasty of specifically the bronchial smooth muscle cell
layer [47]. The heating of the airways led to a decrease in the
amount/mass of BSM [48] and reduced the frequency of
asthmatic exacerbations [49], thus supporting increased BSM
mass as being a key feature of airway remodelling in asthma.
Blocking CXCR2 and thereby inhibiting BSMC-dependent
angiogenesis and associated airway remodelling may therefore
have a similar beneficial effect.
Identification of factors that might ubiquitously regulate
and/or control pathological features in the asthmatic lung
remains a challenge. Our study presents CXCR2-ligands
(GRO-α, ENA-78, IL-8) as candidate factors contributing
toward angiogenesis and airway wall remodelling in asthma.
Studies with CXCR2-blockers and ligand-neutralizing agents in
the context of different diseases (such as rheumatoid arthritis,
COPD) are ongoing [45,50]. Our findings open a door to
exploiting CXCR2-targeted treatments for bronchial asthma as
well.
Supporting Information
Figure S1.  Human angiogenesis antibody array. Examples
of the angiogenesis antibody array (exp. 1) comparing CM from
BSMC of non-asthmatic (A) and asthmatic (B) patients. C,
Antibody array map. Standard abbreviations for the detected
proteins are used, Pos: positive control, Neg: negative control,
IC1-IC3: internal controls 1-3.
(TIF)
Figure S2.  Chemokine release from BSMC derived from
asthmatics and non-asthmatics. This figure illustrates the
concentrations and proportions of the released mediators for
any single subject. Concentrations of GRO-α (A), IL-8 (B) and
ENA-78 (C) in CM collected from BSMC of 6 non-asthmatic
(NA1-NA6) and 6 asthmatic (A1-A6) patients after 72 h
determined by ELISA. Median was calculated from all (A and
NA) * p < 0.05 (n = 6).
(TIF)
Figure S3.  VEGF release by BSMC of asthmatic and non
asthmatic subjects. BSM cells were grown for 72 h in he
presence of 5% FCS and VEGF was measured by ELISA.
Although BSMC-produced VEGF levels are low (<650 pg/ml),
asthmatics (A) release significantly more VEGF compared to
those of non-asthmatics (NA).
(TIF)
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